{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:26:52Z","timestamp":1781278012800,"version":"3.54.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Secondary prevention of patients with chronic coronary syndrome is based on the long-term use of a single anti-aggregating drug which is traditionally represented by acetylsalicylic acid (ASA) in light of the results of studies and meta-analyses which have demonstrated a clear anti-ischaemic efficacy against of an acceptable increase in the risk of bleeding, especially intracranial and gastrointestinal bleeding. The availability of drugs such as clopidogrel, which inhibits platelet activity through the P2Y12 receptor pathway, has called into question this paradigm, also in consideration of the fact that the scientific evidence that supports the use of ASA in secondary prevention is based on dated studies with some limitations. Over the last few years, randomized trials have demonstrated how clopidogrel has an efficacy profile comparable to that of ASA and a safety profile that is sometimes even better. In light of the new evidence, it is therefore legitimate to ask whether in this clinical scenario, ASA should still be considered the drug of choice or whether clopidogrel could represent the preferable alternative.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae022","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:39:59Z","timestamp":1713353999000},"page":"i74-i77","source":"Crossref","is-referenced-by-count":1,"title":["Controversy in cardiology: clopidogrel or acetylsalicylic acid in the treatment of chronic coronary syndromes?"],"prefix":"10.1093","volume":"26","author":[{"given":"Laura","family":"Gatto","sequence":"first","affiliation":[{"name":"Cardiothoracic Department, San Giovanni-Addolorata Hospital , Rome"},{"name":"Center for the Fight against Heart Attack, ONLUS Foundation , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[{"name":"Center for the Fight against Heart Attack, ONLUS Foundation , Rome"},{"name":"Cardiology, Umberto I Hospital\u2014Enna Kore University , Enna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Giuseppe","family":"Biccir\u00e8","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, San Giovanni-Addolorata Hospital , Rome"},{"name":"Center for the Fight against Heart Attack, ONLUS Foundation , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Prati","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, San Giovanni-Addolorata Hospital , Rome"},{"name":"Center for the Fight against Heart Attack, ONLUS Foundation , Rome"},{"name":"UniCamillus\u2014Saint Camillus International University of Health Sciences , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2024051810305756300_suae022-B1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024051810305756300_suae022-B2","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level metaanalysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"Br Med J"},{"key":"2024051810305756300_suae022-B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bmj.296.6618.320","article-title":"Secondary prevention of vascular disease by prolonged antiplatelet treatment","volume":"296","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2024051810305756300_suae022-B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"Br Med J"},{"key":"2024051810305756300_suae022-B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"Br Med J"},{"key":"2024051810305756300_suae022-B6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"2024051810305756300_suae022-B7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2024051810305756300_suae022-B8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2024051810305756300_suae022-B9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cjca.2022.02.029","article-title":"Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease","volume":"38","author":"Abramson","year":"2022","journal-title":"Can J Cardiol"},{"key":"2024051810305756300_suae022-B10","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2024051810305756300_suae022-B11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"2024051810305756300_suae022-B12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i74\/57742808\/suae022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i74\/57742808\/suae022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T10:31:06Z","timestamp":1716028266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/26\/Supplement_1\/i74\/7646211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":12,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae022","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4]]}}}